Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
Abstract
Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 26, 2022
- Source ID
- 10.1111/ene.15373
Entities
People
- Amanda Heslegrave
- Ana F. Ferreira
- Ana Vasconcelos-Ferreira
- Andreas Puschmann
- Cristina Januário
- Gilbert Thomas‐Black
- Hector Garcia-Moreno
- Henrik Zetterberg
- Jeannette Hübener
- Jennifer Faber
- Jon Infante
- Karen Jansen-West
- Kathrin Reetz
- Leonard Petrucelli
- Ludger Schöls
- Luis Pereira De Almeida
- Mafalda Raposo
- Magda Santana
- Manuela Lima
- Matthis Synofzik
- Mercedes Prudencio
- Nita Solanky
- Paola Giunti
- Rana Hanna Al-Shaikh
- Sorina Gorcenco
- Thomas Klockgether
- Zbigniew K Wszolek
Organizations
- ALS Association
- Alzheimer Forschung Initiative
- European Research Council
- Federal Ministry of Research, Technology and Space
- German Center for Neurodegenerative Diseases
- German Research Foundation
- Lund University
- Mayo Clinic
- Mayo Clinic Graduate School of Biomedical Sciences
- Medical Research Council
- National Ataxia Foundation
- RWTH Aachen University
- Sahlgrenska University Hospital
- Swedish Research Council
- Target ALS
- United States Department of Defense
- University College London
- University Hospital Bonn
- University of Coimbra
- University of Porto
- University of Tübingen